Condition

Chronic Spontaneous Urticaria clinical trials and research

• 11Clinical trials
• 1NIH research projects
• 11Countries

Newest Chronic Spontaneous Urticaria clinical trials

All recruiting trials (11)

• Remibrutinib and omalizumab-based treatment approach for adults with chronic spontaneous urticaria not well controlled by antihistamines

  This trial tests a sequencing plan using remibrutinib and omalizumab to see if it helps adults with chronic spontaneous urticaria that isn’t well controlled by second-generation antihistamines.

  Recruiting at 10 sites Phase 3 Novartis · London, Ontario and 9 other locations · NCT07816328

• BBT001 in adults with chronic spontaneous urticaria

  This trial tests whether BBT001 given by IV is safe and can help reduce urticaria in adults who have chronic spontaneous hives.

  Recruiting Phase 1/2 Bambusa Therapeutics · Wuhu, Anhui and 9 other locations · NCT07717905

• Remibrutinib in real-world care for Chronic Spontaneous Urticaria in Germany

  This study looks at how well and how safely remibrutinib works for adults with chronic spontaneous urticaria in real clinical practice after doctors decide to switch or escalate treatment.

  Recruiting Novartis · Düren · NCT07642557

• Testing single and multiple oral doses of EDP-978 in healthy adults

  This study will test how safe and tolerable single and multiple oral doses of EDP-978 are in healthy adults and will measure how the body absorbs and responds to the drug.

  Recruiting Phase 1 Enanta Pharmaceuticals, Inc · San Antonio, Texas · NCT07540910

• Remibrutinib for adults with chronic spontaneous urticaria in routine care

  This prospective US study will see if remibrutinib helps adults with chronic spontaneous urticaria in real-world clinical practice using patient-reported outcome questionnaires.

  Recruiting Novartis · East Hanover, New Jersey · NCT07408219

• JYB1904 Injection for Chronic Spontaneous Urticaria in Adults

  This trial tests whether JYB1904 injections help adults with chronic spontaneous hives that aren’t well controlled by standard antihistamines.

  Recruiting Phase 3 Jemincare · Beijing · NCT07402213

• Remibrutinib use in everyday US care for chronic spontaneous urticaria

  This US sub-study will test remibrutinib's real-world safety and effectiveness for adults with chronic spontaneous urticaria who are escalating or switching from second-generation H1 antihistamines.

  Recruiting Novartis · Kirksville, Missouri · NCT07358780

• Remibrutinib use in everyday clinical care for chronic spontaneous urticaria

  This project sees if remibrutinib helps adults with chronic spontaneous urticaria who need higher‑dose second‑generation antihistamines or are switching to remibrutinib.

  Recruiting Novartis · Kirksville, Missouri · NCT07358364

• Ritlecitinib for chronic spontaneous urticaria (chronic hives) in adults

  This trial will try daily oral ritlecitinib (50 mg or 100 mg) to see if it reduces hives and itching in adults with chronic spontaneous urticaria not controlled by antihistamines.

  Recruiting at 77 sites Phase 2 Pfizer · Phoenix, Arizona and 76 other locations · NCT07219615

• Tacabrutideg (BGB-16673) for Chronic Spontaneous Urticaria: Safety and PK in Adults and Healthy Volunteers

  This Phase 1b study tests whether multiple doses of tacabrutideg are safe and well tolerated in adults with CSU and in healthy people.

  Recruiting Phase 1 BeOne Medicines · Beijing, Beijing Municipality and 8 other locations · NCT07005713

• Evaluating JYB1904 for Chronic Spontaneous Urticaria

  This study is testing a new injection called JYB1904 to see if it can help adults with chronic hives and itching who haven't found relief with regular allergy medications.

  Recruiting Phase 2 Jemincare · Beijing, Beijing Municipality · NCT06509334

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding the role of Prostaglandin D2 in chronic skin allergies

  This study is looking into how a substance called Prostaglandin D2 might be causing allergic reactions in people with chronic spontaneous urticaria (CSU), which affects about 1 in 100 people, to help find new treatment options for those who aren't getting better with current medicines.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10660944

Related topics

Quick answers

How many Chronic Spontaneous Urticaria clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in China (5 trials), United States (5 trials), Canada (2 trials), Germany (2 trials), Japan (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 3: 2, Phase 1: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →